In consensus, the American Association of Clinical Endocrinology’s (AACE) Clinical Practice Guidelines state that CGM is recommended for all persons with diabetes treated with intensive insulin therapy, and CGM may be recommended for individuals with type 2 diabetes (T2D) who are treated with less intensive insulin therapy (21). Here, INS is linked to type 2 diabetes mellitus.